Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. After all, shares of Tempus AI, a healthcare-oriented artificial intelligence (AI) leader, have soared more than 54% year to date (as of this writing), while the S&P 500 has plunged over 5%.But there's no need to fret that you've missed the boat on Tempus AI stock. While its climb so far in 2025 is impressive, it's easy to see how this specialist in applying AI to the field of oncology can skyrocket even higher in the future.Since its founding in 2015, Tempus AI has made great strides in advancing its AI solutions for the treatment of cancer. The company, in fact, characterizes itself as possessing what it "consider[s] to be one of the largest libraries of clinical and molecular oncology data in the world." It's with this resource that Tempus is able to provide physicians with a powerful diagnostic tool that helps to inform better treatment options.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool